- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.03. | Longeveron Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease | 194 | GlobeNewswire (Europe) | Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer's diseaseAlignment with FDA on proposed trial study design... ► Artikel lesen | |
| 14.03. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 11.03. | Longeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B) in Alzheimer's Disease | 168 | GlobeNewswire (Europe) | Phase 2a results demonstrated laromestrocel (Lomecel-B) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's diseaseThis encouraging clinical trial data... ► Artikel lesen | |
| 03.03. | Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript | 1 | Insider Monkey | ||
| 28.02. | Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update | 293 | GlobeNewswire (Europe) | Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more... ► Artikel lesen | |
| 28.02. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.02. | Longeveron Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 18.02. | Longeveron Announces World Health Organization Approval of "laromestrocel" as International Non-proprietary Name for Stem Cell Therapy Lomecel-B | 1 | GlobeNewswire (USA) | ||
| 30.01. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.12.24 | Longeveron to Present at Biotech Showcase 2025 | 3 | GlobeNewswire (USA) | ||
| 13.11.24 | Longeveron reports Q3 results | 3 | Seeking Alpha | ||
| 12.11.24 | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.11.24 | A Look Ahead: Longeveron's Earnings Forecast | 5 | Benzinga.com | ||
| 11.11.24 | Longeveron ernennt Devin Blass zum neuen CTO | 2 | Investing.com Deutsch | ||
| 11.11.24 | Longeveron names Devin Blass as new CTO | 1 | Investing.com | ||
| 11.11.24 | Longeveron Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) | 2 | GlobeNewswire (USA) | ||
| 04.11.24 | Peeling Back The Layers: Exploring Longeveron Through Analyst Insights | 1 | Benzinga.com | ||
| 27.10.24 | Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting | 124 | GlobeNewswire (Europe) | Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none... ► Artikel lesen | |
| 09.10.24 | Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 07.10.24 | Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day | 4 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 87,00 | -3,87 % | BioNTech: Lob für Daten - Goldman Sachs sagt "Kaufen" | Die Aktie von BioNTech ist zuletzt auch im Zuge der veröffentlichten Zahlen für das vergangene Geschäftsjahr sowie den Ausblick auf das laufende Jahr wieder unter Druck geraten. Zuletzt ist das Papier... ► Artikel lesen | |
| CUREVAC | 2,792 | -3,72 % | CureVac Aktie: Bemerkenswerter Aufschwung! | Der Tübinger Impfstoffhersteller meldet beeindruckendes Quartalsergebnis mit 542,57 Millionen USD Umsatz, während die Aktie zwischen 2,06 und 4,98 EUR schwankt. Die CureVac-Aktie zeigte am Donnerstag... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 34,500 | -2,27 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Transition of Chief Operating Officer | ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious... ► Artikel lesen | |
| OCUGEN | 0,643 | -3,89 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
| CYTODYN | 0,200 | 0,00 % | CytoDyn Inc.: March 2025 Letter to Shareholders | VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. ("CytoDyn" or the "Company"). On February 24... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,067 | 0,00 % | SOL Global Investments Corp.: SOL Global Announces Update on C$10 Million Debenture Private Placement from Strategic Investor | Toronto, Ontario--(Newsfile Corp. - March 21, 2025) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), one of the first publicly traded companies focused on institutional... ► Artikel lesen | |
| CELLECTIS | 1,268 | +0,16 % | Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update | ? UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 8,260 | -6,67 % | Anavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update | Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| CERUS | 1,308 | +0,46 % | Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update | CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product revenue guidance for... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 1,490 | -9,70 % | Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules | WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech... ► Artikel lesen | |
| APTEVO THERAPEUTICS | 1,300 | -15,80 % | Aptevo Therapeutics Inc. - S-1/A, General form for registration of securities | ||
| TRACON PHARMACEUTICALS | 1,410 | 0,00 % | Tracon Pharmaceuticals, Inc. - 15-12G, Securities registration termination | ||
| HARVARD BIOSCIENCE | 0,555 | 0,00 % | Harvard Bioscience, Inc.: Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results | HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company") today announced financial results for the fourth quarter and full year ended December 31... ► Artikel lesen | |
| ENTERA BIO | 1,690 | +1,20 % | Entera Bio Ltd.: OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders | MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies... ► Artikel lesen | |
| XBRANE BIOPHARMA | 0,011 | -28,75 % | Xbrane Biopharma AB: Xbrane has entered into an agreement to sell XB003 (Cimzia biosimilar candidate) and parts of its organization to Alvotech for a total consideration of SEK 275 million | Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has entered into an agreement to sell XB003 (biosimilar candidate to Cimzia) and parts of its organization, including approximately 40 employees... ► Artikel lesen |
LONGEVERON INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,035 (-2,02 %) liegt der Kurs bei 1,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.
